Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Welcome and Introduction to Vi3C

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Sep
27
Today In Oncology
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
Robert Kyle Myeloma Expert Dies at 98
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo